0000896622FALSE00008966222024-10-242024-10-24

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
October 24, 2024
Date of Report (Date of earliest event reported)
AptarGroup, Inc.
(Exact name of registrant as specified in its charter)
Delaware001-1184636-3853103
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
265 Exchange Drive, Suite 301, Crystal Lake, Illinois 60014
(Address of principal executive offices)
Registrant’s telephone number, including area code: 815-477-0424.
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $.01 par valueATRNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company    ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐


Item 2.02      Results of Operations and Financial Condition.
On October 24, 2024, AptarGroup, Inc. announced certain information related to its results of operations for the quarter ended September 30, 2024. The press release regarding this announcement is furnished as Exhibit 99.1 hereto.
The information in Item 2.02 of this Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 9.01      Financial Statements and Exhibits.
(d) Exhibits
99.1
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AptarGroup, Inc.
Date:  October 24, 2024
By:/s/ Robert W. Kuhn
Robert W. Kuhn
Executive Vice President and
Chief Financial Officer


Exhibit 99.1
image.jpg
Aptar Reports Third Quarter 2024 Results
Crystal Lake, Illinois, October 24, 2024 -- AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong third quarter results due to solid operational performance and margin improvement across the company. Results were driven by growth in proprietary drug delivery systems, as well as increased demand for closure technologies. Reported sales and core sales increased by 2%, as currency and acquisition effects did not impact the quarter. Aptar reported net income of $100 million for the quarter, a 19% increase from the prior year.
“Aptar delivered another strong quarter driven by our Pharma and Closures segments. We saw increased demand for our proprietary drug delivery systems, active material science solutions and closure technologies, especially for food applications. The Beauty segment saw growth in the personal care and home care markets, but it was not enough to offset tough comparisons from tooling and fragrance dispensing solutions from the prior year period. All three segments continued to demonstrate solid operational performance and margin improvement. We are proud of the strong results and progress we have made for the first nine months of the year and are positioned to achieve double-digit adjusted EPS growth for the full year,” said Stephan B. Tanda, Aptar President and CEO.
Third Quarter 2024 Highlights
•Reported and core sales increased 2%
•Reported earnings per share increased 17% to $1.48 and adjusted earnings per share increased 6% to $1.49
•Reported net income of $100 million increased 19% and adjusted EBITDA increased 8% from the prior year to $208 million, delivering an adjusted EBITDA margin of 23%, which is at the high end of the long-term target range
•Pharma segment delivered reported sales growth of 8% and core sales growth of 7% with continued demand for proprietary drug delivery systems, which grew double digits in the quarter
•Closures segment achieved a solid quarter, with sales and margins within its long-term target ranges
•Earlier this month, closed the previously announced joint venture transaction in China, following regulatory approvals, strengthening dispensing technology footprint

First Nine Months 2024 Highlights
•Double-digit earnings per share growth over the prior year period
•Net cash provided by operations increased to $465 million compared to $356 million in the prior year period
•Free cash flow increased to $255 million compared to $124 million in the prior year
Third Quarter Results
For the quarter ended September 30, 2024, reported sales increased 2% to $909 million compared to $893 million in the prior year. Core sales, which were not impacted by currency exchange rates and acquisitions, increased 2%.

1

Third Quarter Segment Sales Analysis
(Change Over Prior Year)
Aptar
Pharma		Aptar
Beauty		Aptar
Closures		Total AptarGroup
Reported Sales Growth8%(7)%3%2%
Currency Effects (1)
(1)%1%1%0%
Acquisitions0%0%0%0%
Core Sales Growth7%(6)%4%2%
(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.
Aptar Pharma’s reported sales increased 8% from the prior year quarter and core sales were up 7%. The segment’s strong performance was driven by continued demand for proprietary drug delivery systems, which grew double digits in the quarter after growing double digits in the prior year period. Growth in the third quarter was driven by allergy, emergency medicine and central nervous system therapeutics, as well as growing royalty revenues, boosting margins to 36%, which is at the top end of the long-term range. The Active Material Science division also grew double digits, with demand increasing across a number of end markets.
Aptar Beauty’s reported sales decreased 7%, and including currency effects core sales were down 6% compared to the prior year quarter. Approximately 4% of the decline in core sales can be attributed to lower tooling sales, with less favorable product mix contributing the remaining 2% of the decline. While revenue increased from the personal care and home care markets, this increase could not offset the challenging comparisons from prestige fragrance sales in the prior year period. Sales in North America improved progressively, while the Chinese beauty market remains soft. Margins were up year over year for Beauty, with improved operational performance and cost management remaining important points of focus for the segment.
Aptar Closures’ reported sales increased 3% from the prior year quarter and the segment’s core sales increased 4%. The increase in core sales was driven mainly by demand for closures in the food end market. Closures delivered a solid quarter and was within its long-term target ranges for both core sales and adjusted EBITDA margins. The segment’s margins increased by nearly 200 basis points over the prior year quarter, due to increased plant utilization and ongoing cost containment efforts.
Aptar reported third quarter earnings per share of $1.48, an increase of 17%, compared to $1.26 during the same period a year ago. Third quarter adjusted earnings per share, excluding restructuring charges and the unrealized gains or losses on an equity investment, were $1.49, an increase of 6%, compared to $1.40 in the prior year, including comparable exchange rates. The third quarter had an effective tax rate of 24% compared to the prior year period effective tax rate of 23%.
Year-To-Date Results
For the nine months ended September 30, 2024, reported sales increased 3% to $2.73 billion compared to $2.65 billion in the prior year. Core sales, which were not impacted by currency exchange rates and acquisitions, also increased 3%.
Nine Months Year-To-Date Segment Sales Analysis
(Change Over Prior Year)
Aptar
Pharma		Aptar
Beauty		Aptar
Closures		Total AptarGroup
Total Reported Sales Growth9%(3)%1%3%
Currency Effects (1)
0%0%1%0%
Acquisitions0%0%0%0%
Core Sales Growth9%(3)%2%3%
(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.
For the nine months ended September 30, 2024, Aptar’s reported earnings per share were $4.05, an increase of 22%, compared to $3.32 reported a year ago. Current year adjusted earnings per share, excluding restructuring charges, acquisition costs, and the unrealized gains or losses on an equity investment, were $4.12 and increased 15% from prior year adjusted earnings per share of $3.58, including comparable exchange rates. The current year had an effective tax rate of 23% comparable to the prior year period effective tax rate of 25%.

2

Outlook
Regarding Aptar’s outlook, Tanda stated, “Looking to the fourth quarter, we anticipate a solid finish to a strong year. The top line is expected to grow in the fourth quarter, even with some customers having indicated seasonal inventory right-sizing in the beauty and cough & cold end markets. Our pharma business should finish full year 2024 within its core sales long-term target range of 7-11%, driven by demand for allergy medication, emergency medicine and central nervous system therapies. The segment will deliver solid, double-digit adjusted EBITDA growth in 2024 due in part to sales of higher value products and royalties. Our Closures segment has returned to growth and we expect a strong finish to 2024, with healthy adjusted EBITDA margin improvements over the prior year. Beauty is battling a tough macro environment but continues to focus on the bottom line. Innovation, cost mitigation, improved operational leverage and accelerating efficiencies remain key priorities for our teams.”
Aptar currently expects earnings per share for the fourth quarter of 2024, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $1.22 to $1.30. This guidance is based on an effective tax rate range of 20% to 22% with a comparable adjusted prior year effective tax rate of 24%. The earnings per share guidance range is based on spot rates at the end of September for all currencies. Based on the fourth quarter guidance, full year adjusted EPS would be in the range of $5.34 to $5.42, a double-digit increase over full year 2023.
Share Repurchase Authorization and Cash Dividend
As previously reported, Aptar’s Board of Directors authorized the repurchase of $500 million of the Company’s common stock. This new authorization replaces all previous authorizations. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. The Board also approved the quarterly cash dividend of $0.45 per share. The payment date is November 14, 2024, to stockholders of record as of October 24, 2024. During the third quarter, Aptar repurchased 95 thousand shares for approximately $14 million.
Open Conference Call
There will be a conference call held on Friday, October 25, 2024 at 8:00 a.m. Central Time to discuss the company’s third quarter results for 2024. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations website at investors.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website.
About Aptar
Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has more than 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

3

Presentation of Non-GAAP Information
This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar’s management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect Aptar’s core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar’s management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of the company's routine activities, such as restructuring and acquisition costs.

4

This press release contains forward-looking statements, including certain statements set forth under the “Outlook” section of this press release. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide including the invasion of Ukraine by the Russian military and the recent events in the Middle East and the resulting indirect impact on demand from our customers selling their products into these countries, as well as rising input costs and certain supply chain disruptions; the availability of raw materials and components (particularly from sole sourced suppliers for some of our Pharma solutions) as well as the financial viability of these suppliers; lower demand and asset utilization due to an economic recession either globally or in key markets we operate within; economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth; the execution of our fixed cost reduction initiatives, including our optimization initiative; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs (particularly resin, metal, anodization costs and energy costs); significant fluctuations in foreign currency exchange rates or our effective tax rate; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key accounts; our ability to successfully implement facility expansions and new facility projects; our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases; changes in capital availability or cost, including rising interest rates; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired, including contingent consideration valuation; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; cybersecurity threats against our systems and/or service providers that could impact our networks and reporting systems; the impact of natural disasters and other weather-related occurrences; fiscal and monetary policies and other regulations; changes, difficulties or failures in complying with government regulation, including FDA or similar foreign governmental authorities; changing regulations or market conditions regarding environmental sustainability; work stoppages due to labor disputes; competition, including technological advances; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers’ products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts
Investor Relations Contact:
Mary Skafidas
mary.skafidas@aptar.com
815-479-5530
Media Contact:
Katie Reardon
katie.reardon@aptar.com
815-479-5671

5

AptarGroup, Inc.
Condensed Consolidated Financial Statements (Unaudited)
(In Thousands, Except Per Share Data)
Consolidated Statements of Income
Three Months Ended
September 30,
Nine Months Ended
September 30,
2024
2023
2024
2023
Net Sales$909,291 $892,997 $2,734,802 $2,648,970 
Cost of Sales (exclusive of depreciation and amortization shown below)558,511 566,691 1,708,707 1,697,824 
Selling, Research & Development and Administrative141,604 138,137 443,714 427,488 
Depreciation and Amortization67,015 62,686 196,332 184,212 
Restructuring Initiatives3,864 6,161 9,659 19,628 
Operating Income138,297 119,322 376,390 319,818 
Other Income (Expense):
Interest Expense(12,290)(9,984)(32,526)(29,900)
Interest Income3,022 946 9,022 2,266 
Net Investment Gain (Loss)1,043 (1,240)1,495 1,839 
Equity in Results of Affiliates(77)1,002 (168)1,514 
Miscellaneous Income (Expense), net1,136 3 (518)(1,341)
Income before Income Taxes131,131 110,049 353,695 294,196 
Provision for Income Taxes31,209 25,751 80,382 72,265 
Net Income$99,922 $84,298 $273,313 $221,931 
Net Loss (Gain) Attributable to Noncontrolling Interests117 (2)284 201 
Net Income Attributable to AptarGroup, Inc.$100,039 $84,296 $273,597 $222,132 
Net Income Attributable to AptarGroup, Inc. per Common Share:
Basic$1.51 $1.28 $4.13 $3.39 
Diluted$1.48 $1.26 $4.05 $3.32 
Average Numbers of Shares Outstanding:
Basic66,445 65,707 66,274 65,550 
Diluted67,716 67,035 67,574 66,865 

6

AptarGroup, Inc.
Condensed Consolidated Financial Statements (Unaudited)
(continued)
($ In Thousands)
Consolidated Balance Sheets
September 30, 2024December 31, 2023
ASSETS
Cash and Equivalents$325,524 $223,643 
Short-term Investments2,387 — 
Accounts and Notes Receivable, Net698,989 677,822 
Inventories488,540 513,053 
Prepaid and Other150,164 134,761 
Total Current Assets1,665,604 1,549,279 
Property, Plant and Equipment, Net1,505,209 1,478,063 
Goodwill968,293 963,418 
Other Assets486,109 461,130 
Total Assets$4,625,215 $4,451,890 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Short-Term Obligations$253,112 $458,220 
Accounts Payable, Accrued and Other Liabilities773,540 793,089 
Total Current Liabilities1,026,652 1,251,309 
Long-Term Obligations822,731 681,188 
Deferred Liabilities and Other222,191 198,095 
Total Liabilities2,071,574 2,130,592 
AptarGroup, Inc. Stockholders' Equity2,539,009 2,306,824 
Noncontrolling Interests in Subsidiaries14,632 14,474 
Total Stockholders' Equity2,553,641 2,321,298 
Total Liabilities and Stockholders' Equity$4,625,215 $4,451,890 

7

AptarGroup, Inc.
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)
($ In Thousands)
Three Months Ended
September 30, 2024
ConsolidatedAptar PharmaAptar BeautyAptar ClosuresCorporate
& Other		Net Interest
Net Sales$909,291 $420,594 $302,859 $185,838 $— $— 
Reported net income$99,922 
Reported income taxes31,209 
Reported income before income taxes131,131 120,243 17,839 18,042 (15,725)(9,268)
Adjustments:
Restructuring initiatives3,864 564 1,962 877 461 
Curtailment gain related to restructuring initiatives(1,851)— — (1,851)— 
Net investment gain(1,043)— — — (1,043)
Adjusted earnings before income taxes132,101 120,807 19,801 17,068 (16,307)(9,268)
Interest expense12,290 12,290 
Interest income(3,022)(3,022)
Adjusted earnings before net interest and taxes (Adjusted EBIT)141,369 120,807 19,801 17,068 (16,307)— 
Depreciation and amortization67,015 30,787 20,420 14,912 896 
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)$208,384 $151,594 $40,221 $31,980 $(15,411)$— 
Reported net income margins (Reported net income / Reported Net Sales)11.0 %
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)22.9 %36.0 %13.3 %17.2 %
Three Months Ended
September 30, 2023
ConsolidatedAptar PharmaAptar BeautyAptar ClosuresCorporate
& Other		Net Interest
Net Sales$892,997 $389,188 $323,980 $179,829 $— $— 
Reported net income$84,298 
Reported income taxes25,751 
Reported income before income taxes110,049 108,113 17,415 11,647 (18,088)(9,038)
Adjustments:
Restructuring initiatives6,161 92 2,880 3,098 91 
Net investment loss1,240 — — — 1,240 
Realized gain on investments included in net investment loss above4,188 — — — 4,188 
Adjusted earnings before income taxes121,638 108,205 20,295 14,745 (12,569)(9,038)
Interest expense9,984 9,984 
Interest income(946)(946)
Adjusted earnings before net interest and taxes (Adjusted EBIT)130,676 108,205 20,295 14,745 (12,569)— 
Depreciation and amortization62,686 28,139 20,775 12,862 910 
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)$193,362 $136,344 $41,070 $27,607 $(11,659)$— 
Reported net income margins (Reported net income / Reported Net Sales)9.4 %
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)21.7 %35.0 %12.7 %15.4 %

8

AptarGroup, Inc.
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)
($ In Thousands)
Nine Months Ended
September 30, 2024
ConsolidatedAptar PharmaAptar BeautyAptar ClosuresCorporate
& Other		Net Interest
Net Sales$2,734,802 $1,242,420 $951,666 $540,716 $— $— 
Reported net income$273,313 
Reported income taxes80,382 
Reported income before income taxes353,695 335,409 57,808 42,883 (58,901)(23,504)
Adjustments:
Restructuring initiatives9,659 653 5,871 2,530 605 
Curtailment gain related to restructuring initiatives(1,851)— — (1,851)— 
Net investment gain(1,495)— — — (1,495)
Transaction costs related to acquisitions140 — 140 — — 
Adjusted earnings before income taxes360,148 336,062 63,819 43,562 (59,791)(23,504)
Interest expense32,526 32,526 
Interest income(9,022)(9,022)
Adjusted earnings before net interest and taxes (Adjusted EBIT)383,652 336,062 63,819 43,562 (59,791)— 
Depreciation and amortization196,332 89,198 62,174 42,697 2,263 
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)$579,984 $425,260 $125,993 $86,259 $(57,528)$— 
Reported net income margins (Reported net income / Reported Net Sales)10.0 %
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)21.2 %34.2 %13.2 %16.0 %
Nine Months Ended
September 30, 2023
ConsolidatedAptar PharmaAptar BeautyAptar ClosuresCorporate
& Other		Net Interest
Net Sales$2,648,970 $1,135,934 $979,956 $533,080 $— $— 
Reported net income$221,931 
Reported income taxes72,265 
Reported income before income taxes294,196 288,603 46,643 39,174 (52,590)(27,634)
Adjustments:
Restructuring initiatives19,628 1,657 12,650 4,060 1,261 
Net investment gain(1,839)— — — (1,839)
Realized gain on investments included in net investment gain above4,188 — — — 4,188 
Transaction costs related to acquisitions255 — 199 56 — 
Adjusted earnings before income taxes316,428 290,260 59,492 43,290 (48,980)(27,634)
Interest expense29,900 29,900 
Interest income(2,266)(2,266)
Adjusted earnings before net interest and taxes (Adjusted EBIT)344,062 290,260 59,492 43,290 (48,980)— 
Depreciation and amortization184,212 81,248 61,883 38,097 2,984 — 
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)$528,274 $371,508 $121,375 $81,387 $(45,996)$— 
Reported net income margins (Reported net income / Reported Net Sales)8.4 %
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)19.9 %32.7 %12.4 %15.3 %

9

AptarGroup, Inc.
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)
(In Thousands, Except Per Share Data)
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
Income before Income Taxes$131,131 $110,049 $353,695 $294,196 
Adjustments:
Restructuring initiatives3,864 6,161 9,659 19,628 
Curtailment gain related to restructuring initiatives(1,851)— (1,851)— 
Net investment (gain) loss(1,043)1,240 (1,495)(1,839)
Realized gain on investments included in net investment (gain) loss above— 4,188 — 4,188 
Transaction costs related to acquisitions— — 140 255 
Foreign currency effects (1)1,261 1,491 
Adjusted Earnings before Income Taxes$132,101 $122,899 $360,148 $317,919 
Provision for Income Taxes$31,209 $25,751 $80,382 $72,265 
Adjustments:
Restructuring initiatives1,013 1,611 2,471 5,170 
Curtailment gain related to restructuring initiatives(478)— (478)— 
Net investment (gain) loss(255)304 (366)(450)
Realized gain on investments included in net investment (gain) loss above— 1,026 — 1,026 
Transaction costs related to acquisitions— — 35 65 
Foreign currency effects (1)295 366 
Adjusted Provision for Income Taxes$31,489 $28,987 $82,044 $78,442 
Net Loss (Income) Attributable to Noncontrolling Interests$117 $(2)$284 $201 
Net Income Attributable to AptarGroup, Inc.$100,039 $84,296 $273,597 $222,132 
Adjustments:
Restructuring initiatives2,851 4,550 7,188 14,458 
Curtailment gain related to restructuring initiatives(1,373)— (1,373)— 
Net investment (gain) loss(788)936 (1,129)(1,389)
Realized gain on investments included in net investment (gain) loss above— 3,162 — 3,162 
Transaction costs related to acquisitions— — 105 190 
Foreign currency effects (1)966 1,125 
Adjusted Net Income Attributable to AptarGroup, Inc.$100,729 $93,910 $278,388 $239,678 
Average Number of Diluted Shares Outstanding67,716 67,035 67,574 66,865 
Net Income Attributable to AptarGroup, Inc. Per Diluted Share$1.48 $1.26 $4.05 $3.32 
Adjustments:
Restructuring initiatives0.04 0.07 0.11 0.22 
Curtailment gain related to restructuring initiatives(0.02)— (0.02)— 
Net investment (gain) loss(0.01)0.01 (0.02)(0.02)
Realized gain on investments included in net investment (gain) loss above— 0.05 — 0.05 
Transaction costs related to acquisitions— — — — 
Foreign currency effects (1)0.01 0.01 
Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share$1.49 $1.40 $4.12 $3.58 
(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates.

10

AptarGroup, Inc.
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited)
(In Thousands)
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
 
Net Cash Provided by Operations$229,262 $173,401 $465,174 $355,602 
Capital Expenditures(66,550)(76,187)(210,416)(231,199)
Free Cash Flow$162,712 $97,214 $254,758 $124,403 

11

AptarGroup, Inc.
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)
(In Thousands, Except Per Share Data)
Three Months Ending
December 31,
Expected 2024
2023
Income before Income Taxes$80,629 
Adjustments:
Restructuring initiatives25,376 
Net investment loss426 
Transaction costs related to acquisitions225 
Foreign currency effects (1)2,206 
Adjusted Earnings before Income Taxes$108,862 
Provision for Income Taxes$18,384 
Adjustments:
Restructuring initiatives6,769 
Net investment loss104 
Transaction costs related to acquisitions56 
Foreign currency effects (1)503 
Adjusted Provision for Income Taxes$25,816 
Net Loss Attributable to Noncontrolling Interests$110 
Net Income Attributable to AptarGroup, Inc.$62,355 
Adjustments:
Restructuring initiatives18,607 
Net investment loss322 
Transaction costs related to acquisitions169 
Foreign currency effects (1)1,703 
Adjusted Net Income Attributable to AptarGroup, Inc.$83,156 
Average Number of Diluted Shares Outstanding67,131 
Net Income Attributable to AptarGroup, Inc. Per Diluted Share (3)$0.93 
Adjustments:
Restructuring initiatives0.28 
Net investment loss— 
Transaction costs related to acquisitions— 
Foreign currency effects (1)0.03 
Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share (2)$1.22 - $1.30$1.24 
(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using spot rates as of September 30, 2024 for all applicable foreign currency exchange rates.
(2) AptarGroup’s expected earnings per share range for the fourth quarter of 2024, excluding any restructuring expenses, acquisition costs and changes in fair value of equity investments, is based on an effective tax rate range of 20% to 22%. This tax rate range compares to our fourth quarter of 2023 effective tax rate of 23% on reported earnings per share and 24% on adjusted earnings per share.

12
v3.24.3
Cover
Oct. 24, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Oct. 24, 2024
Entity Registrant Name AptarGroup, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-11846
Entity Tax Identification Number 36-3853103
Entity Address, Address Line One 265 Exchange Drive
Entity Address, Address Line Two Suite 301
Entity Address, City or Town Crystal Lake
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60014
City Area Code 815
Local Phone Number 477-0424
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $.01 par value
Trading Symbol ATR
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0000896622
Amendment Flag false
AptarGroup (NYSE:ATR)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas AptarGroup.
AptarGroup (NYSE:ATR)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas AptarGroup.